Daiichi Sankyo Company, Limited (DSKYF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - General industria. La empresa tiene su sede en Tokyo, Japan. El CEO actual es Hiroyuki Okuzawa.
DSKYF tiene fecha de IPO 2008-06-24, 18,726 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $32.23B.
Daiichi Sankyo Company, Limited is a Tokyo-based pharmaceutical company founded in 1899 that researches, develops, manufactures, and markets a diverse portfolio of prescription and over-the-counter medicines globally. The company's core therapeutic areas include oncology, cardiovascular disease, diabetes, pain management, and infectious disease, with key products such as Enhertu (trastuzumab deruxtecan) for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo operates across consumer health, vaccines, animal health, cosmetics, and medical devices. The company has established strategic collaborations, including a partnership with Guardant Health to develop companion diagnostics, and maintains a strong commitment to innovation across multiple healthcare segments.
